Laurus Labs Limited has informed the Exchange regarding a press release dated April 30, 2026, titled "Press Release for Q4 FY26".
LAURUSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Laurus Labs reported strong FY26 results with revenues of ₹6,813 crore, up 23% year-on-year, driven by robust growth in CDMO and Affordable Medicines divisions. EBITDA grew 64% to ₹1,826 crore with margins expanding by 6.7 percentage points to 26.8%, while net profit surged 148% to ₹889 crore. Q4 FY26 showed steady performance with revenues of ₹1,812 crore (+5%) and EBITDA of ₹523 crore (+10%). CDMO division led growth with 36% revenue increase to ₹2,080 crore, while the Bio segment posted exceptional 124% growth in Q4. The company declared a second interim dividend of ₹1.2 per share and announced increased CAPEX investment to support future growth in peptides, fermentation, and gene therapy capabilities.
Strong operational performance with margin expansion signals improving profitability and scale benefits. The 148% jump in net profit and declaration of dividend are positive for shareholders, while increased CAPEX intensity suggests confidence in future growth prospects.